Biological aging results from molecular and cellular damage over time. This process determines a progressive decrease in physical and functional capacity, an increased risk of disease and death. Therefore, the identification of the molecular mechanisms of aging has led to research for senotherapeutic strategies. Metformin is an oral hypoglycaemic drug. It is the first choice for the treatment of type 2 diabetes mellitus (T2DM). However, clinical and preclinical evidence has shown the beneficial effects of metformin also in cardiovascular diseases, neurodegenerative diseases, and aging. This editorial explores the recent evidence on metformin as an anti-aging drug.